SVA: A modern solution to an uncomfortable problem

Livewire Equities

Livewire

Incontinence is more than an uncomfortable topic - it's a booming global problem traditionally managed at high cost for aged care providers. Simavita's (ASX: SVA) SIM system is the first of its kind to create evidence-based care plans for incontinence sufferers – delivering significant patient and cost benefits. New pilot programs and increasing sales are fueling interest in the digital healthcare company with Hong Kong-based fund manager Ward Ferry taking a cornerstone position in Simavita as it seeks to raise up to $8.2 million. Darren Vincent, Research Analyst at Shaw Stockbroking, says the sector is seeing a renaissance of investor interest. "6 - 12 months ago we couldn't get any interest. However, the success of stories like Nanosonics and Impedimed have got people trying to work out which company will be next." In his latest note, Darren highlights recent progress being made by Simavita and shares his target price and recommendation. Access the research here: (VIEW LINK)


Livewire Equities
Livewire Equities
Livewire

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.